Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas

Keyphrases

• Adverse Reactions 5%
• Bromocriptine 100%
• Clinical Management 100%
• Clinical Practice 5%
• D2 Receptor 5%
• Daily Dose 11%
• Dopamine Agonist 100%
• Dopamine D2 Receptor (DRD2) 5%
• Ergot Derivatives 5%
• Headache 5%
• Hypotension 5%
• Large Series 5%
• Long Duration of Action 5%
• Macroprolactinoma 100%
• Medical Approach 5%
• MRI Scan 5%
• Nausea-vomiting 5%
• Quinagolide 5%
• Tumor Mass 5%
• Tumor Shrinkage 5%
• Visual Field Defect 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 5%
• Bromocriptine 100%
• Dopamine Receptor D2 5%
• Dopamine Receptor Stimulating Agent 100%
• Ergot Derivative 5%
• Headache 5%
• Hypotension 5%
• Nausea 5%
• Neoplasm 11%
• Prolactinoma 100%
• Quinagolide 5%
• Receptor 5%
• Visual Field Defect 5%